PMID: 18714668Aug 22, 2008Paper

A preliminary gene expression profile of acute graft-versus-host disease

Cell Transplantation
Matthew P BuzzeoVijay Reddy

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for high-risk hematological malignancies, yet a major complication associated with this therapy is acute graft-versus-host disease (GVHD). Despite a well-defined pathophysiological mechanism, there are no definitive markers for predicting acute GVHD development or progression to advanced stages. In the current study, we enrolled four acute GVHD and four acute GVHD-free recipients of allogeneic HSCT and collected peripheral blood just prior to onset of clinical acute GVHD for analysis on Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays. We noted significant differences in expression of 1,658 genes between control and acute GVHD patients, based on an analysis of covariance (ANCOVA) by type of transplant, a pooled error estimate, and a false discovery rate (FDR) of 10%. In conclusion, we offer the first report of a preliminary molecular signature of acute GVHD in allogeneic HSCT patients.

References

Nov 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T WerfelJ Zwirner
May 11, 2002·Nature Reviews. Immunology·Marcel R M van den Brink, Steven J Burakoff
Oct 15, 2003·Blood Reviews·Pavan Reddy, James L M Ferrara
May 27, 2004·The American Journal of Pathology·Philip B SugermanMarcel R M van den Brink
Nov 19, 2004·Physiological Genomics·Robert J FeezorUNKNOWN Inflammation and Host Response to Injury, Large-Scale Collaborative Research Program
Jan 15, 2005·Cell Transplantation·Tobias BergZhiguang Guo
Jun 3, 2005·Clinical Medicine & Research·Tsuyoshi Iwasaki
Mar 16, 2006·American Journal of Physiology. Gastrointestinal and Liver Physiology·Stephan BrandJulia Dambacher
Jun 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Motomu ShimizuTakayuki Yoshimoto
Mar 24, 2007·PLoS Medicine·Chantal BaronClaude Perreault
Sep 1, 2004·Cell Transplantation·Tobias BergZhiguang Guo

❮ Previous
Next ❯

Citations

Dec 17, 2009·BMC Bioinformatics·Jun WuYajun Yi
May 22, 2009·Expert Opinion on Biological Therapy·Matthew D ScaifeJ A Medin
May 31, 2011·Toxicology in Vitro : an International Journal Published in Association with BIBRA·S EhnertA K Nussler
Apr 15, 2011·Immunological Reviews·Maria-Grazia RoncaroloRosa Bacchetta
Mar 4, 2014·Stem Cells·Malte von Bonin, Martin Bornhäuser
Oct 30, 2014·Journal of Cellular and Molecular Medicine·Christopher OelkrugStephan Fricke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.